An abstract of the work that was accomplished with the 2018 faculty development funds follows below. Also, Dr. Gallagher presented this work in Washington, D.C. as part of the national meeting in this field (see reference below). In addition Dr. Gallagher made use of the data analyzed as part of the Faculty Development Award as preliminary data in grants submitted to the National Science Foundation (one of which is now funded, and one of which is pending), see references below.

**Presentation at National Meeting:**

**Carla J. Gallagher,** Kathleen M. Schieffer, Gregory S. Yochum, Walter A. Koltun. Use of the Informatics for Integrating Biology and the Bedside (i2b2) population to test serum bilirubin levels and risk for inflammatory bowel diseases and the involvement of uridine glucuronosyltransferase genes. *ACM conference on Bioinformatics, Computational Biology and Health Informatics.* Washington, D.C. August 2018.

**New External Grant Funding in 2018:**

**Pending:**

National Science Foundation (NSF), HBCU-UP, Targeted Infusion Project. “HBCU Undergraduate Bioinformatics Program at Lincoln University.”

Role: Dr. Gallagher, Co-PI with Dr. Miller (Pending, submitted Nov 2018).

$400,000 over 3 years.

**Awarded:**

National Science Foundation (NSF), Planning Grant. “Planning Grant for TIP to Implement a HBCU Undergraduate Bioinformatics Program at Lincoln University.”

Role: Dr. Gallagher, Co-PI with Dr. Miller

$179,846 (6/15/18-1/31/20) – original $149,996 plus 2 supplements

**Abstract:**

Chronic inflammation associated with inflammatory bowel disease (IBD) results in increased oxidative stress that damages the colonic microenvironment. A low level of serum bilirubin, an endogenous antioxidant, has been associated with increased risk for Crohn’s disease (CD), but no study has tested another common IBD ulcerative colitis (UC). Bilirubin is metabolized in the liver by uridine glucuronosyltransferase 1A1 (UGT1A1) exclusively. Genetic variants cause functional changes in UGT1A1 which result in hyperbilirubinemia, which can be toxic to tissues if untreated and results in a characteristic jaundiced appearance. Approximately 10% of the Caucasian population is homozygous for the microsatellite polymorphism *UGT1A1*28, which results in increased total serum bilirubin levels due to reduced transcriptional efficiency of UGT1A1 and an overall 70% reduction in UGT1A1 enzymatic activity. The aim of this study was to examine whether bilirubin levels are associated with the risk for ulcerative colitis (UC). Using the Informatics for Integrating Biology and the Bedside (i2b2), a large case-control
population was identified from a single tertiary care center, Penn State Hershey Medical Center (PSU). Similarly, a validation cohort was identified at Virginia Commonwealth University Medical Center. Logistic regression analysis was performed to determine the risk of developing UC with lower concentrations of serum bilirubin. From the PSU cohort, a subset of terminal ileum tissue was obtained at the time of surgical resection to analyze UGT1A1 gene expression (which encodes the enzyme responsible for bilirubin metabolism). Similar to CD patients, UC patients also demonstrated reduced levels of total serum bilirubin. Upon segregating serum bilirubin levels into quartiles, risk of UC increased with reduced concentrations of serum bilirubin. These results were confirmed in our validation cohort. UGT1A1 gene expression was up-regulated in the terminal ileum of a subset of UC patients. Lower levels of the antioxidant bilirubin may reduce the capability of UC patients to remove reactive oxygen species leading to an increase in intestinal injury. One potential explanation for these lower bilirubin levels may be up-regulation of UGT1A1 gene expression, which encodes the only enzyme involved in conjugating bilirubin. Therapeutics that reduce oxidative stress may be beneficial for these patients.